Thomas Lampron formally announced on LinkedIn this week that he is 'thrilled to join the powerhouse team at Revolution Medicines' as VP, global commercial pancreas lead, ending a 13-year career with Merck.
June 5, 2026 07:00 AM EDT
Peer Review
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
Alex Hoffman
Copy Chief and News Editor
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
Novo underwhelmed by drug it once fought Pfizer for
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
What RevMed's pancreatic cancer drug meant for one patient
Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US
Silvia Luque announced on LinkedIn that she was named head of US marketing at Zealand Pharma. She had been executive director of…
As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. | As…
Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics.
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral…
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Biohaven Announces Scientific Leadership Transitions
